Trials with monoclonal antibodies discussed at AD/PD 2019

Trials with monoclonal antibodies discussed at AD/PD 2019

April 29, 2019 0 Comments

At the 2019 International Congress on Alzheimer’s Disease (AD) and Parkinson’s disease (PD) in Lisbon, Portugal, scientists and researchesr presented the new opportunities and the lessons learnt in trials with monoclonal antibodies (mAbs). This followed all the failures that affected the AD pipeline, especially in AD drugs targeting the amyloid pathways, such as Roche’s crenezumab and lastly Biogen/Eisai aducanumab, the most promising drug in the AD pipeline. Several clinical trials of mAbs we...

Read More

Trials with monoclonal antibodies discussed at AD/PD 2019

Trials with monoclonal antibodies discussed at AD/PD 2019

April 29, 2019 0 Comments

At the 2019 International Congress on Alzheimer’s Disease (AD) and Parkinson’s disease (PD) in Lisbon, Portugal, scientists and researchesr presented the new opportunities and the lessons learnt in trials with monoclonal antibodies (mAbs). This followed all the failures that affected the AD pipeline, especially in AD drugs targeting the amyloid pathways, such as Roche’s crenezumab and lastly Biogen/Eisai aducanumab, the most promising drug in the AD pipeline. Several clinical trials of mAbs we...

Read More